Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

People who take weight-loss drugs hoping to achieve the impressive results observed in large clinical trials may need to ...

Regeneron acquired a promising weight management asset that could become lucrative. Shares of Regeneron (NASDAQ: REGN) have declined this year due to issues with one of its former growth drivers, ...

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Variants of obesity-related genes influence how much weight patients lose on specific weight loss drugs like liraglutide, two studies report.

Last week, Australia’s Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnoea, a ...

Novo Nordisk and Deep Apple ink a deal to develop oral therapies targeting a novel GPCR for cardiometabolic diseases, ...

Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.

Part of the appeal of amylin analogs is the potential to drive weight loss without causing the same level of tolerability problems as GLP-1 receptor agonists. Lilly reported relatively low rates of ...

The study included electronic ... better obesity drugs. “The unmet clinical need is a medicine that’s well tolerated, that gives us 15 or 20% weight loss, is affordable and is accessible ...

Novo Nordisk (NVO) stock gains as the company launches a new Phase 3 trial for its next-gen weight loss drug CagriSema after ...